A comparative study of the efficacy and toxicity of etodolac and naproxen in the treatment of osteoarthritis.
In a two-period, double-blind, crossover study, patients with osteoarthritis of the knee and/or hip received etodolac 300 mg twice daily for 4 weeks and naproxen 500 mg twice daily for 4 weeks in random order. The assessment of efficacy showed that naproxen and etodolac were equally effective in the management of pain and stiffness in osteoarthritis. However, a significantly higher proportion of patients preferred naproxen to etodolac for the relief of pain intensity. The incidence of adverse events caused by either drug was the same.
Chikanza
I C
IC
Department of Rheumatology, United Medical School, Guy's Hospital, London.
Clarke
B
B
Hopkins
R
R
MacFarlane
D G
DG
Bird
H
H
Grahame
R
R
D000293:Adolescent; D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D017308:Etodolac / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007719:Knee Joint; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000627:therapeutic use*; D010003:Osteoarthritis / Q000188:drug therapy*; D015207:Osteoarthritis, Hip / Q000188:drug therapy; D016896:Treatment Outcome
D017308:Etodolac; D009288:Naproxen